Studies of beta-thromboglobulin, platelet factor 4, and fibrinopeptide A in erythrocytosis due to cyanotic congenital heart disease
- PMID: 6189239
- DOI: 10.1016/0049-3848(83)90144-5
Studies of beta-thromboglobulin, platelet factor 4, and fibrinopeptide A in erythrocytosis due to cyanotic congenital heart disease
Abstract
Plasma and serum assays of beta-thromboglobulin (BTG) and platelet factor 4 (PF4), and plasma fibrinopeptide A (FPA) were measured in adults with cyanotic congenital heart disease to characterize further the hemostatic disorder. Artifactual elevations of plasma BTG, PF4, and FPA appeared to occur occasionally when a 21 or 22 gauge needle was used to collect blood. The high packed red cell volume was probably the cause. Use of a larger caliber needle (20 gauge) appeared to lessen the problem. Normal plasma FPA levels (20 gauge needle) in 8 of 9 patients suggest that chronic intravascular coagulation is not common in these patients. Serum BTG and PF4, used to estimate total platelet content of these proteins, were normal to slightly increased. That levels were not reduced implies that platelets do not usually circulate in a "spent" state. Therapeutic phlebotomy in 8 patients was associated with small decreases in plasma BTG and PF4 of uncertain clinical significance. Five of 14 patients had elevated plasma BTG with normal to only minimally increased plasma PF4. However, 10 of 10 patients tested were found to have reduced creatinine clearance, and therefore the relative contributions of platelet secretion and reduced BTG catabolism in the kidney to elevated plasma BTG levels are unclear.
Similar articles
-
Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus.Diabetes Care. 1984 Mar-Apr;7(2):174-9. doi: 10.2337/diacare.7.2.174. Diabetes Care. 1984. PMID: 6203689
-
Radioimmunoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrinopeptide A generation.Br J Haematol. 1978 May;39(1):129-46. doi: 10.1111/j.1365-2141.1978.tb07135.x. Br J Haematol. 1978. PMID: 78721
-
Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease.Blood. 1982 Sep;60(3):650-4. Blood. 1982. PMID: 6179552
-
Platelet-released proteins as molecular markers for the activation process.Semin Thromb Hemost. 1984 Oct;10(4):270-9. doi: 10.1055/s-2007-1004432. Semin Thromb Hemost. 1984. PMID: 6240116 Review.
-
Platelet markers of thromboembolic disease.West J Med. 1981 Jul;135(1):19-24. West J Med. 1981. PMID: 6167074 Free PMC article. Review.
Cited by
-
Hypertrophic osteoarthropathy: endothelium and platelet function.Clin Rheumatol. 1996 Sep;15(5):435-9. doi: 10.1007/BF02229639. Clin Rheumatol. 1996. PMID: 8894355
-
Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View.Acta Cardiol Sin. 2015 Nov;31(6):507-15. doi: 10.6515/acs20150424b. Acta Cardiol Sin. 2015. PMID: 27122915 Free PMC article. Review.
-
Effect of 8 hours of hyperinsulinaemia on haemostatic parameters in healthy man.Diabetologia. 1989 Aug;32(8):606-10. doi: 10.1007/BF00285335. Diabetologia. 1989. PMID: 2528492 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous